CEO Interview: Ulcerative Colitis Trial Shows Abivax's HIV Candidate Has Broader Potential

05 Sep 2018

• By Sten Stovall

Abivax Phase IIa data for its lead asset showed impressive results in ulcerative colitis. The biotech's CEO tells Scrip trials in Crohn's disease and rheumatoid arthritis will now follow.

Gastrointestinal tract — Abivax Says Good Phase II Data In UC Transforms Pipeline Prospects • Source: Shutterstock

Abivax will start trialing its novel lead compound in other anti-inflammation conditions after a Phase IIa trial showed ABX464 to be safe and effective in ulcerative colitis patients who are refractive to current therapies, including anti-TNF treatment, the French biotech's CEO told Scrip.

Orally administered ABX464 had already shown good results in a recently completed Phase II clinical trial to demonstrate it can...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

06 Jun 2025

• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

04 Jun 2025

• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.